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Summary The optimal use of mitoxantrone (NOV) in the high-dose range requires elucidation of its maximum tolerated dose with peripheral
blood progenitor cell (PBPC) support and the time interval needed between drug administration and PBPC reinfusion in order to avoid graft
toxicity. The aims of this study were: (1) to verify the feasibility and haematological toxicity of escalating NOV up to 90 mg m-2 with PBPC
support; and (2) to verify the safeness of a short (96 h) interval between NOV administration and PBPC reinfusion. Three cohorts of ten
patients with breast cancer (BC) or non-Hodgkin's lymphoma (NHL) received escalating doses of NOV, 60, 75 and 90 mg m-2 plus melphalan
(L-PAM), 140-180 mg m-2, with PBPC rescue 96 h after NOV. Haematological toxicity was evaluated daily (WHO criteria). NOV plasma
pharmacokinetics was also evaluated, as well as NOV cytotoxicity against PBPCs. Haematological recovery was rapid and complete at each
NOV dose level without statistically significant differences, and there were no major toxicities. NOV plasma concentrations at the time of
PBPC reinfusion were below the toxicity threshold against haemopoietic progenitors. It is concluded that, when adequately supported with
PBPCs, NOV can be escalated up to 90 mg m-2 with acceptable haematological toxicity. PBPCs can be safely reinfused as early as 96 h after
NOV administration.
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High-dose chemotherapy is commonly based on alkylating agents,
mainly because of the myeloid dose-limiting toxicity, the steep
dose-response curve in vitro and the favourable dose ratio (with a
four- to tenfold escalation with respect to conventional doses) of
these drugs (Frei and Canellos, 1980; Frei, 1995). However, the
growing extension of high-dose chemotherapy to solid tumours
and the development ofmultistep high-dose programmes have led
to a broader use ofdrugs belonging to different classes and acting
by different mechanisms (Gianni and Bonadonna, 1989).
Among the non-alkylating agents, mitoxantrone (NOV), an
anthraquinone compound thatis active against a variety ofhaemato-
logical and solid tumours, has received considerable attention. In
fact, NOV has haematological dose-limiting toxicity with reportedly
limited cardiotoxicity compared with other anthracyclines, can be
escalated at least five times above the conventional dose and clearly
exhibits a steep dose-response curve in vitro (Von Hoffet al, 1986).
Thus, it has been included in several high-dose regimens delivered
with haematopoietic rescue (Mulder et al, 1989; Ellis et al, 1990;
Wallerstein et al, 1990; Bowers et al, 1993; Attal et al, 1994; Stiffet
al, 1994; Patrone et al, 1995). However, it has been claimed that
very high dosages imply haematological toxicity that cannot be
adequately rescued even by haematopoietic progenitor cell reinfu-
sion (Attal et al, 1994). A special matter ofconcern arises from its
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prolonged plasma half-life and possible toxicity to reinfused pro-
genitors, especially at higher dosages. This is why a prolonged
interval between NOV administration and haematopoietic rescue is
often recommended, which may involve some disadvantages,
mainly because delaying reinfusion delays haematological recovery.
In this study we tested the feasibility of administering NOV
safely with peripheral blood progenitor cell (PBPC) support in the
dose range 60-90 mg m-2, and we also addressed the issue of
haematopoietic rescue timing. For these purposes, clinical and
pharmacokinetic evaluations were carried out in patients under-
going high-dose treatments including NOV at dosages of 60, 75
and 90 mg m-2. Furthermore, the cytotoxicity threshold ofthe drug




Thirty consecutive patients eligible for high-dose chemotherapy
programmes including a conditioning regimen with NOV and
melphalan (L-PAM) were enrolled in the present study. In order to
assess haematological and non-haematological toxicity of esca-
lating doses of NOV, administered at supposedly myeloablative
doses with PBPC rescue, three cohorts of ten patients each were
treated at the dose levels of60, 75 and 90 mg m-2, provided that no
major toxicity was observed at the lower dose level before esca-
lating the dose. Haematological toxicity was evaluated by daily
blood sampling and toxic effects were registered and graded
according to the World Health Organization (WHO) criteria. The
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Table 1 Patient characteristics
Dose level of NOV (mg m-2)
Characteristic 60 75 90 Pa
Total number of patients 10 10 10
Age (years)
Median 44 35 45 NS
Range 26-55 18-57 32-52
Sex (male/female) 5/5 2/8 1/9
Previous therapy (score)b
Median 1 1 1 NS
Range 0-4 0-3 0-4
Performance status .80 > 80 .80 NS
Haematological parameters fore high-dose chemotherapy:
WBC (x 10 1-1)
Median 5.420 5.070 6.915 NS
Range (3.100-7.930) (3.480-10.400) (3.940-11.690)
Neutrophils (x 1091-1)
Median 3.800 3.400 4.435 NS
Range (1.770-7.030) (2.150-9.360) (2.360-8.700)
Platelets (x 1091-1)
Median 300 311.5 269.5 NS
Range (192-433) (172-450) (195-369)
Hb (mg dl-1)
Median 11.4 12.1 12.3 NS
Range (10.3-14.8) (10.2-13.1) (9.1-13.4)
Bone marrow involvement No No No
CY-NOV + L-PAM interval (days)
Median 26 28 26 NS
Range (19-39)- (23-54) (20-67)
Neutrophils before NOV (x 109 1-1)
Median 4.675 3.5 4.585 NS
Range (0.99-19.730) (1.350-14.6) (2.32-10)
Disease (BC/NHL) 4/6 6/4 8/2
aKruskall-Wallis test. bPrevious therapy score: 0, no previous chemoradiotherapy; 1, less than one course of standard-dose chemotherapy; 2, one complete
course of standard-dose chemotherapy (six cycles); 3, more than one course of standard-dose chemotherapy; radiotherapy add one point to chemotherapy score.
three patient groups were well matched for factors that might
influence haematopoietic recovery, as detailed in Table 1.
In order to evaluate the possible cytotoxic effect of residual
plasma NOV on the graft, the plasma pharmacokinetics of NOV
was evaluatedbyhigh-performanceliquidchromatography(HPLC)
in 13 patients and the correlation between theplasmaconcentration
ofthe drug at the time ofreinfusion and thehaematological toxicity
parameters was analysed. Furthermore, the in vitro sensitivity of
haematopoietic progenitor cells to NOV was determined by
measuring the surviving fraction of granulocyte-macrophage
colony-forming units (CFU-GM) exposed to various drug concen-
trations in standard short-term (1 h) as well as in long-term (7 day)
exposure tests.
Patient characteristics and eligibility
Eighteen patients had metastatic breast cancer (BC) and 12 had
intermediate or high-grade non-Hodgkin's lymphoma (NHL).
Among the NHL patients, one was in first relapse and 11 were
poor risk (as defined eitherby group 2-3 international index orby
the presence of bulky disease) at diagnosis (The International
Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993).
The main characteristics of the three groups of patients are listed
in Table 1.
Eligibility criteria included age below 60 years, performance
status . 80% (Karnofsky) and normal heart, lung, liver and renal
function. Patients with bone marrow involvement as determined
by bilateral iliac biopsy, as well as patients with previous or
concomitant neoplasia, diabetes mellitus orbrain metastases, were
excluded. All patients provided written, informed consent in
keeping with institutional ethics committee guidelines.
High-dose chemotherapy
Breast cancer patients received a four-step high-dose treatment as
previously reported (Patrone et al, 1995), including: first,
cyclophosphamide (CY) 6 g m-2; second, NOV 60-90 mg m-2 plus
L-PAM 140-180 mg m-2 and PBPC rescue; third, methotrexate 8 g
m-2 plus vincristine 1.4 mg in-2; and fourth, etoposide 1.5 g m-2
plus carboplatin 1.5 gm-2 and PBPC rescue. NHL patients
received similar treatment except for the metothrexate plus
vincristine step which was omitted.
NOV was dissolved in saline and administered on day - 4 as a
4-h infusion, at the three dose levels of60,75 and 90 mg m-2, with
mild anti-emetic treatment. L-PAM was administered onday - 1, at
180 mg m-2 with the lowest dose ofNOV and at 140 mg m-2 with
the two highest dose levels. The drug was given undiluted in three
divided doses, with intensive i.v. hydration and anti-emetic
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therapy consisting of dexamethasone and ondansetron. Cryo-
preserved PBPCs were reinfused on day 0, i.e. 96 h after NOV
administration. No haematopoietic growth factors were adminis-
tered after PBPC reinfusion.
Haematopoietic progenitor cells
After CY administration patients received subcutaneous haemato-
poietic growth factors (rhGM-CSF or a sequential combination of
rhGM-CSF and rh interleukin 3) until haematological recovery.
PBPCs were collected by continuous flow leucapheresis starting
whenWBC andplateletcounts reached 1.0 x 109 1-' and 50 x 109 1-'
respectively. A median number ofthree aphereses (range 2-5) was
required to collect the planned number of CD34+ cells (2 10 x
106kg-'), which we assumed would conveniently support two
myeloblative cycles.
The apheretic product was cryopreserved in autologous plasma
and 10% dimethylsulphoxide. Cells expressing the CD34 surface
antigen were enumerated cytofluorimetrically with a Coulter
Epics Profile 2 flow cytometer (Coulter, Hialeah, FL, USA) using
the monoclonal antibody fluorescein isothiocyanate (FITC)-
conjugated HPCA-2 (Becton-Dickinson, San Jose, CA, USA)
(Siena et al, 1991).
Pharmacological study
In 13 patients, blood samples for analysis of NOV concentrations
were drawn before drug administration as well as at 1, 2 and 3 h
during the infusion, at the end ofthe 4 h NOV infusion, and there-
after at 5, 15, 30, 45 and 60 min and at 2, 4, 6, 24, 48, 72 and 96 h.
The samples, collected in heparinized tubes, were immediately
placed on ice and then centrifuged at 1800g for 10 min to separate
plasma. Plasma samples, to which was added 10% (v/v) of5% L-
ascorbic acid in citrate buffer (0.1 M, pH 3.0), were frozen at
-200C until processing. Urine samples were collected over 4 h
during infusion and then at successive intervals of 2, 4, 6, 24, 48,
72 and 96 h after the end of infusion. Each urine volume was
recorded and an aliquot was frozen until analysis.
Analysis ofNOV in plasma and urine was carried out by HPLC
according to the method described by Peng et al (1982).
Quantitation was done by the external method of analysis.
Retention time for NOV was 5 min. Extraction efficacy from
plasma and urine was about 90%. The detection limit of the
method was 1 ng ml-'.
Concentrations of NOV vs time were plotted on semiloga-
rithmic graphs. Visual inspection of the post-infusion plasma
concentration-time profiles suggested that the curves were
triphasic in form. Therefore, the plasmaconcentration-time curves
for each patient were analysed according to a three-compartment
open model using a P-Pharm computer program (Simed France)
on an IBM/IC computer. All plasma pharmacokinetics were fitted
to the multiexponential equation: Cp (t) = A exp(- at) + B exp(,t)
+ Cexp(- yt), where Cp (t) is the drug concentration at time t, A, B
and C are constants and a, [, and y are the apparent first-order
elimination rate constants. The area under the concentration vs
time curve (AUC), corrected for the duration of infusion, was
calculated according to Freedman and Workman (1988). Mean
residence time (MRT), steady-state volume of distribution (V,0),
total body clearance (Cl) and the elimination half-lives were
calculated from standard pharmacokinetic equations (Gibaldi and
Perrier, 1982). The renal clearance (ClR) was calculated using the
equation ClR = Du/AUCt, where Du, is the amount of NOV
excreted in urine up to time t after the infusion and AUC, is the
area under the concentration-time curve calculated (trapezoidal
rule) for the same time.
Cytotoxicity assay
NOV cytotoxicity against haematopoietic progenitor cells was
deternmined in a dose-surviving fraction curve by measuring the
number of CFU-GM after in vitro exposure to various concentra-
tions of the drug. PBPC samples from the apheretic product were
exposed to various NOV concentrations that represented the
plasma values measured during pharmacokinetic study, including
the peak plasma concentrations and those measured at the time of
progenitor cell reinfusion. The tests were performed after either a
1-h exposure time or a 7-day exposure time. NOV (Lederle-
Cyanamid S.p.A.) was prepared in 0.9% sodium chloride solution
immediately before use. For the 1-h exposure experiments cells
were suspended in RPMI-1640 medium at 106 ml-', incubated at
370C with gentle shaking and then washed twice before clono-
genic assay. For the 7-day exposure experiments the drug was
directly mixed in clonogemnc assay medium.
CFU-GM surviving fraction was determined in a modified
short-term clonogenic assay (Lemoli and Gulati, 1993). Briefly,
cells were plated in triplicate in 24-well tissue culture plates
(Coming CostarCorporation, Cambridge, MA, USA). The culture
medium consisted of 0.3 ml of Iscove MDM supplemented with
Table 2 Haematological toxicity
Dose level of NOV (mg m-2)
Parameter, median (range) 60 75 90 pa
Days with neutrophils < 0.1 x 109 I-1. 7 (5-9) 7 (5-9) 6 (5-10) NS
Days with neutrophils < 0.5 x 109 Ol 9.5(9-15) 11.5 (8-25) 9.5 (8-18) NS
Days to neutrophils 2 1 x 109 1-1 16 (12-54) 18 (15-28) 18.5 (12-24) NS
Days with platelets < 10 x 1091- 0 (0-1) 0 (0-1) 0.5 (0-4) NS
Days with platelets < 20 x 1091-' 2 (1-4) 1.5 (0-6) 2 (1-9) NS
Units plateletstransfused 1 (0-2) 1 (0-3) 1 (0-3) NS
Units packed RBCs transfused 4 (2-8) 3.5 (2-8) 3 (1-6) NS
Days with neutropenic fever < 38.50C 2 (0-7) 1 (0-7) 1 (0-9) NS
Grade of mucositis 2 (0-4) 1 (0-4) 1.5 (0-4) NS
aKruskallWallis test.
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Table 3 Summary of NOV plasma pharmacokinetics
Dose level of NOV (mg m-2)
Parameter 60 75 90 pa
Number of patients 4 5 4
Peak level (,gl-1) 392 ± 19 602 ± 253 861 ±270 < 0.01
AUCO_<(mg h 1-1) 2.0±0.3 2.9 ± 0.8 4.7± 1.3 < 0.01
MRT (h) 61+ 10 71±25 63± 37 NS
T2,,, (min) 15.0±1.8 13.2 ±1.8 14.4 ±5.4 NS
T,125 (h) 2.6 ± 0.3 2.0 ± 0.1 2.5 ± 0.8 NS
T1,2Y(h) 41 ±7 48±17 42± 16 NS
96 h level (ggI-1) 2.6±1.1 3.4 ±2.3 4.3± 1.8 NS
Cl (I h-1 m-2) 30±4 28±8 21 ±7 NS
VSS (Im-2) 1772 ±139 1832 ±459 1200 ±618 NS
CIR (I h-1) 2.2 ± 0.8 2.0± 0.5 2.4± 1.4 NS
aKendall correlation analysis. Abbreviations: AUC, area under plasma concentration vs time curve; MRT, mean residence
time; CL, total-body clearance; VSS, volume of distribution at steady-state; NS, not significant.
24% fetal calf serum (FCS, Hyclone Europe, UK), 0.8% bovine
serum albumin (BSA, Stem Cell Technologies, Canada), 104 M 2-
mercaptoethanol (Sigma Chemical, St Louis, MO, USA), 10%
5637 medium and 10 ng ml-1 recombinant human granulocyte
colony-stimulating factor (G-CSF, Amgen-Roche, Milan, Italy).
Methylcellulose (Sigma) was added at a final concentration of
1.1%. CFU-GM colonies (. 50 cells) were scored after 7 days
using an inverted microscope. The percentage of survival was
calculated on the basis of three experiments as the ratio between
the number of colonies surviving on cultures treated with NOV,
1 h or 7 days, and the number of colonies growing on control
plates.
Supportive care
All patients were supported in single or double rooms equipped
with a high-efficiency particulate-air filtration unit until they
achieved a neutrophil count 2 1.0 x 1091-1. Transfusions of leuco-
cyte-free packed red blood cells and single-donor platelets were
administered for haemoglobin levels less than 9 g dl-1 and platelet
count less than 10 x 1091-1. All patients received oral prophylaxis
with ciprofloxacin and fluconazole and total parenteral nutrition
when necessary.
Response criteria
Before treatment patients were evaluated by means of physical
examination, complete peripheral blood cell count and chemistry,
chest radiography, chest and abdominal computerized tomo-
graphic scanning and bone marrow biopsy. In addition, breast
cancer patients were evaluated by means of radionuclide bone
scan and tumour markers (CA 15.3, CEA). Patients were restaged
at the end of the sequential chemotherapy programme. Complete
remission (CR) was defined as the disappearance ofall measurable
and assessable disease for at least 1 month. Partial remission (PR)
was defined as a 50% or greater reduction in the product of the
bidimensional measurements of all measured lesions with no new
lesions and no lesions increasing in size. The persistent uptake of
bone scan despite sclerosis ofprevious lytic lesions was defined as
PR. Progressive disease (PD) was defined as a greater than 25%
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Figure 1 Plasma concentration-time profiles of NOV following a 4 h
intravenous infusion at the three dose levels studied. Points represent the
mean of four patients at 60 mg m-2 (0), five patients at 75 mg m-2 (0) and
four patients at 90 mg m-2 (A). -, 4 h infusion time
Statistical analysis
As some data did not fit in with the normal frequency distribution,
median ± SIQ (seminterquartile) were used where appropriate.
Comparisons between groups were madeusing the Kruskall-Wallis
test. Regression analysis was performed using the non-parametric
Theil technique. The presence ofany monotonic trend was assessed
with the Kendall test (Hollander and Wolfe, 1974). Significance
threshold was set at 0.05 level.
RESULTS
Haematological toxicity
The haematological recovery after high-dose CY was fast and
complete in all 30 patients. The median duration of severe
neutropenia (neutrophils < 0.5 x 109 1-1) was 6 days (range 2-10)
and thrombocytopenia was severe (platelets < 20 x 1091-1) in 20%
of patients with a median duration of 2 days (range 1-4). The
subsequent myelosuppressive course, NOV plus L-PAM, was
administered after a median interval of about 4 weeks, 26 days
(range 19-67). This interval was not significantly different in the
three patient groups when discrete data were evaluated (Table 1).
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Figure 2 Survival curves of CFU-GM incubated with various NOV concentrations
mean ± s.e.m. of three experiments
The haematological toxicity parameters registered after NOV
and L-PAM in the three groups of patients are listed in Table 2.
Recovery from cytopenia was rapid and complete in all cases with
a low requirement of single-donor platelet and packed red blood
cell transfusions. In particular high-risk neutropenia (neutrophils
< 0.1 x 109 1-') lasted only about a week and high-risk thrombo-
cytopenia (platelets < 10 x 109 [-l) was negligible. It is ofnote that
no statistically significant differences were observed in the haema-
tological recovery of the three patient groups. As a consequence,
no statistical correlation was found between administered doses of
NOV and the haematological parameters considered in Table 2.
Peripheral progenitor cells
The myelosuppressive treatment with NOV and L-PAM was
supported in all patients with peripheral blood progenitor cells
collected in median 12 days (range 11-15) after high-dose CY. A
median ofthree (range 2-5) leucaphereses were required to collect
the planned number ofCD34-positive cells to support two myelo-
suppressive courses. The median number of CD34-positive cells
reinfused 96 h after NOV (day 0) was 12.4 x 106kg-' (range
5.3-50.3), with no significant differences among the three dose
levels ofNOV (P = 0.110).
Pharmacokinetics of high-dose NOV
Plasma disappearance curves for NOV at the three dose levels
studied are shown in Figure 1. Post-infusion plasma NOV concen-
trations decayed in a triexponential fashion with an elimination
mean half-life of 44.1 ± 17.1 h. Table 3 lists the mean pharmaco-
kinetic parameters for each NOV dose level. The values for clear-
ance (CL, CLR), V 1, MRT, and half-lives were not significantly
different between varying doses. A significant (P < 0.01) correla-
tion was observed between administered doses and peak levels of
0 0 10 1
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s in short-, 1 h (m) and long-term, 7 day (A), in vitro tests. Points represent the
NOV, as well as between administered doses and AUCs. In all
patients, plasma NOV was still detectable on day 0, i.e. 96 h after
drug administration. Measurement of NOV urinary excretion
showed that 1.6%-6.7% (mean 3.6%) of the compound was
excreted within 72 h, independently ofthe dose administered.
Pharmacokinetics-pharmacodynamic relationships
In the 13 cases evaluated, NOV plasma pharmacokinetics did not
correlate with toxicity over the three dose levels. In particular, no
correlation was observedbetweenCmI. andAUC andthedurationof
neutropenia and thrombocytopenia or platelet and red blood cell
requirement or the degree of mucositis. It must also be noted that
these toxicity parameters were not related with the NOV plasma
concentration at96 h, thatis atthe timeofprogenitorcell reinfusion.
Sensitivity of CFU-GM to NOV
To verify the sensitivity of CFU-GM to NOV, samples of the
apheretic products were incubated in vitro with various concentra-
tions ofthe drug, as indicated by thepharmacokinetic analysis, and
the survival fraction was evaluated by clonogenic assay. CFU-GM
showed a high sensitivity to NOV both in short and long-term
exposure tests (Figure 2). However, at low NOV concentrations
(i.e. < 5 ng ml-') the majority ofcells escaped killing, even in long
exposure tests. On the contrary, athigh NOV concentrations nearly
all cells underwent lethal damage, in particular with those similar
to peakplasma concentrations as measured in vivo. In the interme-
diate part of the curves the survival fraction was dose dependent
but, as expected, it showed a steeper course with longerexposures.
It is of note that low doses ofNOV, similar to the residual plasma
concentrations measured at the time of progenitor cell reinfusion,
had very low cytotoxic potential in both short- and long-term in
vitro tests.
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Non-haematological toxicity
Non-haematological toxicity was graded according to the standard
World Health Organization (WHO) system. No treatment-related
deaths occurred. After high-dose CY no clinically relevant toxici-
ties were registered.
At the time of NOV administration four patients (two at 75 and
two at 90 mgm-2) developed a febrile reaction, with chills, greater
than 38°C that was rapidly reversed by hydrocortisone administra-
tion. Mucositis was observed in 23 patients, with a median dura-
tion of 7 days (range 2-24), and was severe enough to require
analgesics and total parenteral nutrition in eight cases. The grading
of mucositis was not found to be related to the administered dose
level ofNOV (Table 2).
Mild elevation of transaminases or bilirubin was observed in
seven patients, WHO grade 1 or 2. No hepatic veno-occlusive
disease was observed.
A 32-year-old patient with metastatic breast cancer had a 16%
asymptomatic decrease in left ventricular ejection fraction (LVEF)
over the baseline value 6 months after NOV 90 mg m-2. At 12
months this patient developed reversible congestive heart failure
andpresented a furtherreduction in LVEF, 35% below the baseline
value. During follow-up no other patients developed clinical
evidence ofcardiotoxicity.
Twenty patients presented neutropenic fever greater than 38.5°C
for a median duration of 2.5 days (range 1-9). No severe infection
with septicaemia was observed. The administered dose level of
NOV was not correlated with the duration ofneutropenic fever.
Response to treatment
Among the 23 evaluable patients (seven patients had non-
evaluable disease after induction chemotherapy or surgery) a high
response rate to the full chemotherapy programme was observed at
all dose levels of NOV. Among the 11 NHL patients, nine
achieved CR (82%), one PR (9%) and one progressed through
therapy with an overall response rate of 90.9%. In the metastatic
breast cancer group the treatment induced CR in 7 out of 12
patients (58.3%) and PR in five (41.7%) with an overall response
rate of 100%.
DISCUSSION
A major end point of the present study was to evaluate whether
NOV can be safely escalated up to 90 mg i-2 when adequately
supported by PBPCs. A second issue was to evaluate the optimal
timing of PBPC reinfusion by determining the time interval
required for plasma drug concentration to fall below the threshold
of cytotoxicity against haematopoietic progenitors. The results
indicate that high-dose NOV can be administered safely in the
range of60-90 mg m-2, provided that adequate numbers ofPBPCs
are given. In fact, in our series high-risk neutropenia lasted on
average 1 week and the duration of thrombocytopenia was negli-
gible with no infectious or haemorrhagic complications and low
transfusional requirement. No treatment-related mortality was
observed and all patients completed the multistep high-dose
chemotherapy as planned.
Different findings were reported by Attal and colleagues (1994)
in a dose-finding study of high-dose NOV supported by bone
marrow transplantation in 20 patients with refractory NHL. These
authors reported a significant increase in haematological toxicity in
a few patients receiving 90 mg m-2 compared with patients
receiving doses ranging from 15 to 75 mg m-2, the mean duration of
severe neutropenia (neutrophils < 0.5 x 1091-') being 31.7 days
(s.d. 8) and 22 days (s.d. 6.5) respectively. Furthermore, they
found a significant relationship between the duration of severe
neutropenia and two pharmacokinetic parameters, Tl4 and day0
plasma concentration (192 h after NOV). Therefore, they
concluded that NOV 90mg mi-2 has a potential risk ofunacceptable
toxicity and that a minimum 8-day delay is required between NOV
administration and graft reinfusion. In contrast, in our study haema-
tological toxicity was the same at all dose levels of NOV and in
particular the mean duration of severe neutropenia with 90 mg mr-2
was not significantly different when compared with the lower dose
groups, that is 11.4 days (s.d. 3.7) vs 11.5 days (s.d. 3.8).
In our series, NOV pharmacokinetics did not differ from that
described previously (Alberts et al, 1985; Ehninger et al, 1986;
Van Belle et al, 1986; Richard et al, 1992; Canal et al, 1993; Attal
et al, 1994). However, the duration of severe neutropenia was
about 50% shorter than that reported by Attal and colleagues
(1994). Furthermore, no delayed haematopoietic failures were
observed over a median follow-up of 26 months (range 6-48) and
no relationship was found between pharmacokinetic and haemato-
logical toxicity parameters in any of the 13 patients studied. To
explain these discrepancies, we could speculate that different
drugs were administered in association with NOV in the two
studies, i.e. CY, BCNU and VP-16 vs L-PAM. However, we
believe that a better explanation can be found by considering
the different haematopoietic rescue. In fact, our patients were
supported with PBPCs (median number of CD34-positive cells
12.4 x 106 kg-', which is well above the known threshold limit for
haematopoietic engraftment; Siena et al, 1991), whereas in the
Attal et al's series bone marrow cells were used. It is well known
(Siena et al, 1993; Martin, 1995) that PBPCs possess a higher bone
marrow-repopulating capacity than bone marrow cells and allow a
more rapid recovery of haematopoietic function. Furthermore,
based on the prolonged plasma half-life of NOV, delays up to 8
days between drug administration and haematopoietic progenitor
reinfusion are recommended (Mulder et al, 1989; Attal et al,
1994). In fact, at that point NOV plasma levels would be lower
than 1 ng ml-, well below the threshold of 2.5 ng ml-' previously
reported to produce a 50% inhibition of CFU-GM in long-term in
vitro tests (Fountzilas et al, 1986). In the scheduling of high-dose
therapy with NOV, however, graft timing is far from trivial, as
anticipating the graft may allow shorter conditioning regimens,
PBPC reinfusion before the onset of aplasia, fewer days of aplasia
and reduced hospital stay. Taking into account these considera-
tions, our patients were administered NOV over a 4-h infusion on
day -4, and PBPCs were reinfused 96 h later when residual plasma
NOV concentrations ranged from 1.5 to 5.5 ng ml-'. All patients
recovered from aplasia and no correlation was found between 96 h
NOV plasma concentrations and measured haematological toxi-
city parameters. These clinical results strongly suggest that
residual NOV at 96 h is devoid of any suppressive effect on rein-
fused progenitor cells. This is also supported by in vitro tests that
were designed assuming that measured plasma concentrations
reflect the bioavailability of the drug on target progenitor cells. In
our experimental conditions, as evaluated by the CFU-GM assay,
NOV concentrations up to 5 ng ml-' were incapable ofinducing a
significant cytotoxic effecton PBPCs. Contrary to what was previ-
ously reported, we were also able to confirm this observation in
long-term exposure tests, that is a 7-day incubation, which might
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be considered a cytotoxicity assay that is more suitable for drugs
with prolonged plasma half-life (Fountzilas et al, 1986). The
absence ofgraft toxicity with 96 h earlier NOV administration has
been recently reported by Stiff et al (1994) in ovarian cancer
patients exposed to high-dose NOV, 75 mg m-2 in three divided
doses, and reinfused with autologous bone marrow.
In our patients non-haematological toxicity was low and
substantially limited to mucositis. Mucositis is a frequent and
important complication ofhigh-dose NOV and L-PAM (Mulder et
al, 1989; Ellis et al, 1990; Wallerstein et al, 1990; Bowers et al,
1993; Attal et al, 1994; Stiffet al, 1994; Patrone et al, 1995). Non-
haematological toxicity was observed in 76% of patients in our
series, and in a third (33%) of them it was of intermediate-high
grade requiring parenteral nutrition and some analgesic treatment.
However, mucositis was not associated with particularly severe
infectious complications, healed promptly after resolution of
neutropenia and did not result in any delay of planned
chemotherapy. Unlike Attal's series with bone marrow rescue
(Attal et al, 1994), there was no correlation between the NOV dose
level and the severity of mucositis in our patients supported by
PBPCS. The duration ofneutropenia was uniformly short, and this
may be a critical factor in determining the clinical evolution of
mucositis, as suggested by the findings of Gabrilove et al (1988),
who found a significant reduction in the incidence and severity of
mucositis when neutrophil recovery after standard dose
chemotherapy was accelerated by G-CSF. In our series, the only
significant organ dysfunction was symptomatic heart failure
observed in a breast cancer patient who presented a decline in
LVEF 12 months after treatment at the 90-mg dose level. Dose-
limiting cardiac toxicity with a maximum tolerated dose as low as
50 mg m-2 was found when NOV was administered with high-dose
thiotepa (Bowers et al, 1993). However, although decreases in
LVEF or clinical signs of heart failure have been noticed, a dose-
limiting heart toxicity has not been found in several studies using
doses of NOV up to 80 mg m-2 in combination with other poten-
tially cardiotoxic agents such as CY and Ara-C (Mulder et al,
1989; Wallerstein et al, 1990; Feldman et al, 1993; Attal et al,
1994; Stiff et al, 1994). The single event observed in our study
does not allow a conclusion to be made on the possible correlation
between NOV dose levels and cardiotoxicity. It is hoped further
information will be available from the prospective study we are
presently running on the long-term survey ofLVEF.
Both breast cancer and lymphoma patients had high response
rates with thepresentmultistep HD treatment. Although itis sugges-
tive that NOV plays a significant role in this result, the present study
was designed neither to compare NOV anti-tumour activity at the
various dose levels nor to establish the relative anti-tumour activity
of NOV in the sequential treatment. However, as our data demon-
strate that PBPCs can overcome the myelosuppressive effect of
doses of NOV up to 90 mg m2, and as containing haematological
toxicity is a critical factor in reducing the overall morbidity of the
treatment, we conclude thatcontrolled studies with high-dose condi-
tioning regimens including NOV up to90 mg m-2 can beplanned for
patients with breast cancer and non-Hodgkin's lymphoma.
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